Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04610658
Title Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung small cell carcinoma

Therapies

Ipilimumab + Lurbinectedin + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.